2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
4
Rare Diseases
across 3 areas
0
News (30d)
Quiet
Alteogen, Inc. is a company with 2 orphan drug designations across 4 rare diseases. gene therapy candidates in 1 disease.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| gastric cancer | antibody drug conjugate of metal-binding motif-introduced trastuzumab antibody variant and monomethyl auristatin E | Des.TrialAppr. |
| isolated growth hormone deficiency type IA | recombinant human growth hormone fused to alpha1-antitrypsin variant | Des.TrialAppr. |
| isolated growth hormone deficiency type IB | recombinant human growth hormone fused to alpha1-antitrypsin variant | Des.TrialAppr. |
| isolated growth hormone deficiency type II | recombinant human growth hormone fused to alpha1-antitrypsin variant | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
8
overlap in 2+ diseases
1/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
8
overlap in 2+ diseases
1/4
candidate diseases
0
avg importance: 0
0
affecting portfolio